10/24/2013

Guido Rasi, executive director of the European Medicines Agency, says that the release of clinical trial data would increase efficiency and cost-effectiveness in drug development, becoming a boon to drug companies rather than creating the loss of competitive advantage they fear. His article, with EMA co-authors, appears in the New England Journal of Medicine. AbbVie and InterMune have filed lawsuits to prevent such data releases.

Full Story:
MedCityNews.com

Related Summaries